Breaking Finance News

Shire PLC (ADR) (NASDAQ:SHPG) has been downgraded from Buy to Hold in a report by HSBC Securities today.

Just yesterday Shire PLC (ADR) (NASDAQ:SHPG) traded -1.63% lower at $198.63. Shire PLC (ADR)’s 50-day moving average is $196.29 and its 200-day moving average is $184.42. The last closing price is up 8.31% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 289,158 shares of SHPG traded hands, down from an average trading volume of 1,252,390

HSBC Securities has downgraded Shire PLC (ADR) (NASDAQ:SHPG) from Buy to Hold in a report released on 09/26/2016.

Recent Performance Chart


Shire PLC (ADR) has PE ratio of 41.51 with a one year low of $147.60 and a one year high of $231.32 and has a market capitalization of $0.

A total of 14 brokerages have issued a ratings update on Shire PLC (ADR). Seven brokerages rating the company a strong buy, seven brokerages rating the company a buy, two brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $241.86.

General Company Details For Shire PLC (ADR) (NASDAQ:SHPG)

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.